Physician profile
Jeffrey A Leavy
NPI 1548211493
$8,120.95
in general payments reported to CMS, 2019-2025
40 companies · $909 in 2025
The $909 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,151 · 2020: $1,261 · 2021: $842 · 2022: $690 · 2023: $1,179 · 2024: $1,089 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,176.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,142.88 | 2019-2025 | Hi-Torque Advance, Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $875.33 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $583.65 | 2019-2025 | Lifevest |
| Pfizer INC. | $503.77 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $490.54 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $437.76 | 2019-2024 | Xarelto |
| Amgen INC. | $431.96 | 2019-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $419.74 | 2023-2025 | Optimizer, Optimizer |
| Esperion Therapeutics, INC. | $378.33 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $353.95 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $351.85 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $310.65 | 2019-2025 | Farxiga, Wainua |
| W. L. Gore & Associates, INC. | $243.06 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.71 | 2019-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $166.40 | 2019-2025 | Evkeeza |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Leavy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.